ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Glycogenesys Inc.  (MM)

Glycogenesys Inc. (MM) (GLGS)

0,00
0,00
(0,00%)
Geschlossen 13 Dezember 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
-
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

GLGS Neueste Nachrichten

GlycoGenesys, Inc. Announces Chapter 11 Filing, Reduction in Work Force and Senior Management Changes

Company Significantly Reduces Expenses To Pursue Strategic Alternatives While Maintaining Multiple Myeloma Clinical Trial BOSTON, Feb. 3 /PRNewswire-FirstCall/ -- GlycoGenesys, Inc...

GlycoGenesys, Inc. Requests Hearing to Appeal Nasdaq Staff Determination

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced that it requested a hearing before a Nasdaq Listing Qualifications Panel to appeal the Nasdaq Staff...

GlycoGenesys, Inc. Comments on 2005 Third Quarter Financial Results and Stock Listing Status; Quarterly Conference Call Schedule

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on drug development, today commented on results from its Form 10-Q for the quarter ended September 30, 2005. ? Select Financial...

GlycoGenesys Initiates Additional Prestigious Medical Site for GCS-100 Phase I/II Multiple Myeloma Clinical Trial; Patient Scree

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company, today announced it has initiated Roswell Park Cancer Institute, (RPCI) Buffalo, New York as a clinical site for its Phase I/II dose...

GlycoGenesys to Present at the Bio-Europe 2005 Partnering Conference

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, announced today that Frederick E. Pierce, II, VP of Business Development will make a corporate presentation at the Bio-Europe...

GlycoGenesys to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

GlycoGenesys, Inc.. (Nasdaq: GLGS), a biotechnology company, announced today that John W. Burns, Sr. VP. And CFO will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on...

GlycoGenesys, Inc. Announces $20.0 Million Common Stock Purchase Agreement with Fusion Capital

GlycoGenesys, Inc. (Nasdaq: GLGS), a biotechnology company, today announced it has entered into a common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional...

ChineseWorldNet.com Inc. to Host Global Chinese Financial Forum in Toronto

VANCOUVER, British Columbia, Sept 27 /PRNewswire/ -- ChineseWorldNet.com Inc. is proud to present the third annual Global Chinese Financial Forum (GCFF) -- Toronto Conference 2005 on October...

New Preclinical Discovery Shows GlycoGenesys' Cancer Drug Candidate GCS-100 Inhibits AKT1 (Promoter of Cancer Cell Survival and

Data Presented At The XI International Work Shop on Chronic Lymphocytic Leukemia ? GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company, today announced that Dr. Finbarr Cotter...

New Mechanistic Frame Work For GlycoGenesys' Cancer Drug Candidate GCS-100 Published in The Journal Cancer Research

? GCS-100 Targets Galectin-3 in Multiple Myeloma Cells In Vitro, Leading to Increased Anti-Tumor Activity When Combined With Dexamethasone ? GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SHOTWSafety Shot Inc
US$ 0,25
(79,21%)
29,07k
PALIPalisade Bio Inc
US$ 2,36
(68,57%)
68,2M
LAESSEALSQ Corporation
US$ 1,8401
(60,01%)
256,79M
HIMXHimax Technologies Inc
US$ 9,73
(45,22%)
20,06M
TRVITrevi Therapeutics Inc
US$ 3,60
(44,58%)
63,85M
SPGCSacks Parente Golf Inc
US$ 0,3621
(-74,14%)
29,71M
KROSKeros Therapeutics Inc
US$ 18,40
(-73,20%)
14,65M
TFFPTFF Pharmaceuticals Inc
US$ 0,0657
(-59,62%)
13,29M
SFHGSamfine Creation Holdings Group Ltd
US$ 1,27
(-58,36%)
7,38M
APVOAptevo Therapeutics Inc
US$ 5,60
(-44,06%)
6,49M
GOEVCanoo Inc
US$ 0,1737
(33,62%)
970,8M
LAESSEALSQ Corporation
US$ 1,8401
(60,01%)
256,79M
NVDANVIDIA Corporation
US$ 137,34
(-1,41%)
159,23M
RGTIRigetti Computing Inc
US$ 5,9591
(-19,25%)
158,72M
CDTConduit Pharmaceuticals Inc
US$ 0,0798
(-9,63%)
119,28M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock